# Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

> **NCT01199861** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 138 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Fingolimod
- **DRUG:** Placebo
- **BIOLOGICAL:** Seasonal influenza vaccine
- **BIOLOGICAL:** Tetanus toxoid vaccine

## Key facts

- **NCT ID:** NCT01199861
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2012-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199861, "Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01199861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*